ARVINAS, INC. (ARVN)

Arvinas is a biopharmaceutical company that has staked its entire mission on protein degradation—a radically different approach to drug design compared to decades of pharmaceutical tradition. Rather than developing molecules that merely inhibit or block a protein’s function, the company engineers therapeutics that actually cause disease-causing proteins to be marked for destruction and removed by the body’s natural cellular waste disposal system. This mechanism, built on their proprietary PROTAC (PROteolysis TArgeting Chimera) platform, works by bringing together the offending protein and an E3 ubiquitin ligase, two molecules that would normally never meet, triggering a chain of events that sends the target protein to the proteasome for degradation. The approach is particularly valuable for addressing proteins long dismissed as “undruggable”—proteins with shapes or binding properties that made traditional inhibition strategies impossible.

The company has moved beyond pure platform validation. In partnership with Pfizer, Arvinas brought VEPPANU (vepdegestrant) to FDA approval for estrogen receptor-positive, HER2-negative breast cancers driven by ESR1 mutations—marking the first-ever FDA green light for a PROTAC-based drug and demonstrating to the market that protein degradation is no longer theoretical. This achievement fundamentally changed how investors and pharmaceutical executives view the technology, shifting it from “interesting research” to “real therapeutics.”

Pipeline and Therapeutic Areas

Arvinas has expanded beyond breast cancer into multiple cancer types and neurological conditions, each presenting different scientific and commercial challenges. The company’s portfolio reflects both near-term clinical-stage programs and longer-horizon bets on proteins that have resisted conventional drug approaches.

The neurological programs, particularly ARV-102 for Parkinson’s disease targeting the LRRK2 mutation, showcase the platform’s versatility. These medicines must cross the blood-brain barrier—a feat that requires both PROTAC chemistry innovation and pharmaceutical expertise many companies lack. The KRAS G12D program represents one of oncology’s most ambitious scientific targets, one that has consumed billions in research across the industry with limited success until protein degradation approaches emerged as potentially viable.

Arvinas operates in a deeply competitive biotechnology landscape where intellectual property, scientific talent, and clinical execution determine outcomes. Patent protection around PROTAC chemistry gives the company a window before competitors with similar approaches commercialize. However, that window is limited; multiple companies have entered the protein degradation space, and the regulatory bar for next-generation programs will be raised by VEPPANU’s approval. The company’s ability to move programs through clinical development efficiently, secure additional partnership validations, and maintain cash runway through the capital-intensive middle years of drug development will define its long-term trajectory.